Reston, VA-Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy, according to new research published in the January issue of The Journal of Nuclear Medicine. By comparing healthy contralateral breast tissue of patients with malignant breast tumors and benign breast tumors, researchers found that multiple differences in biomarkers can be assessed with PET/MRI imaging, which could impact risk-adapted screening and risk-reduction strategies in clinical practice.
To
read more please visit:
https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=33317
Source: Society of Nuclear Medicine and Molecular Imaging